Welcome to our dedicated page for Alector news (Ticker: ALEC), a resource for investors and traders seeking the latest updates and insights on Alector stock.
Alector, Inc. develops clinical-stage biotechnology programs for neurodegenerative diseases, using genetics, immunology and neuroscience to pursue therapies that remove toxic proteins, replace missing proteins and restore immune and nerve cell function. News about ALEC commonly covers the Alector Brain Carrier (ABC) blood-brain barrier platform and ABC-enabled programs across antibodies, enzymes and siRNA.
Company updates focus on Alzheimer’s disease, Parkinson’s disease, Lewy body dementia, frontotemporal dementia and other tauopathies, including candidates such as AL137, AL050 and AL064/AL164, as well as prior clinical programs including nivisnebart and latozinemab. Recurring announcements also include financial results, cash runway commentary, clinical trial results or discontinuations, research pipeline progress, investor conference participation and executive leadership changes.
Alector, a clinical-stage biotechnology company pioneering immuno-neurology, has announced participation in several upcoming virtual investor conferences. Key events include:
- Citi’s 16th Annual Biopharma Virtual Conference: Sept 8 at 11:35 a.m. ET and Sept 9 at 1:25 p.m. ET.
- Wells Fargo Virtual Healthcare Conference: Sept 10 at 2:00 p.m. ET.
- Morgan Stanley 19th Annual Global Healthcare Conference: Sept 13 at 11:45 a.m. ET.
Webcasts will be available on the Alector website, with replays for 30 days.
Alector (NASDAQ: ALEC) reported its Q2 2021 financial results, highlighting collaboration revenue of $6.6 million, up from $3.2 million year-over-year. The company continues to advance its AL001 program in frontotemporal dementia (FTD-GRN), presenting twelve-month data showing a 47% clinical progression slowdown. Alector and GSK established a global partnership, granting Alector $700 million upfront and up to $1.5 billion in potential milestones. As of June 30, 2021, cash and investments totaled $319.6 million, sufficient for operations into mid-2024.
Alector, Inc. (Nasdaq: ALEC) reported promising outcomes from its Phase 2 INFRONT-2 study of AL001, targeting frontotemporal dementia (FTD) due to progranulin gene mutations. At the Alzheimer’s Association International Conference, data showed that AL001 restored progranulin to normal levels and slowed clinical progression by 47% compared to a matched control group. Safety results indicated a favorable profile with mild adverse effects in a small patient cohort. Alector plans to proceed with a Phase 3 study, further assessing AL001's efficacy and safety in FTD patients.
Alector, Inc. (Nasdaq: ALEC) announced an oral presentation on July 29, 2021, regarding the Phase 2 study of AL001 for frontotemporal dementia with a progranulin mutation, at the 2021 Alzheimer’s Association International Conference. The six- and twelve-month data from the open-label INFRONT-2 study will be discussed by Dr. Robert Paul, CMO. Additionally, two posters will present the AL002 Alzheimer’s disease program, including Phase 1 study results and INVOKE-2 trial design. The conference call will be held at 1:00 p.m. ET to review findings.
Alector and GSK have formed a strategic collaboration to co-develop monoclonal antibodies AL001 and AL101 aimed at treating multiple neurodegenerative diseases. This partnership includes a $700 million upfront payment and up to $1.5 billion in potential milestones. Alector will lead clinical development up to Phase 2, while both companies will share commercialization responsibilities in the U.S., with GSK handling international rights. The collaboration could significantly expand treatment options for conditions like frontotemporal dementia, ALS, Parkinson's, and Alzheimer’s.
Alector, a clinical-stage biotechnology company specializing in immuno-neurology, announced that Dr. Shehnaaz Suliman will participate in two upcoming investor conferences. The events include the Goldman Sachs 42nd Annual Global Healthcare Conference on June 10, 2021, at 4:40 p.m. ET, and the BofA Securities 2021 Napa Biopharma Virtual Conference on June 14, 2021, at 5:30 p.m. ET. Live webcasts will be accessible on Alector's website, with replays available for 30 days post-event. Alector is focused on developing therapies for neurodegenerative diseases by targeting immune dysfunction.
Alector, Inc. (Nasdaq: ALEC) announced a virtual key opinion leader event on frontotemporal dementia due to a progranulin gene mutation (FTD-GRN) scheduled for June 11, 2021, at 10:30 a.m. ET. The agenda includes discussions on FTD-GRN pathophysiology, clinical endpoints, and disease-relevant biomarkers. Key presentations will be made by esteemed neurology experts, including Henrik Zetterberg and Jonathan Rohrer. The event will be webcast live on Alector's website. AL001, an investigational monoclonal antibody for FTD-GRN, has received Orphan Drug and Fast Track designations from the FDA.
Alector, a clinical-stage biotechnology company specializing in immuno-neurology, announced participation by its president and COO, Shehnaaz Suliman, in a fireside chat at the BofA Securities 2021 Virtual Health Care Conference on May 13, 2021, at 11:45 a.m. ET. A live webcast will be accessible on the Alector website, with a replay available for 30 days post-event. Alector focuses on innovative therapies for neurodegenerative diseases, emphasizing innate immune system repair and targeting genetic mutations in neurodegenerative conditions.
Alector, Inc. (Nasdaq: ALEC) reported key business updates and financial results for Q1 2021. The company is actively enrolling patients in the AL001 INFRONT-3 Phase 3 trial for frontotemporal dementia and the AL002 INVOKE-2 Phase 2 trial for early Alzheimer's disease. Collaboration revenue dropped to $4.1 million from $7.2 million year-over-year. R&D expenses rose significantly to $45.7 million, contributing to a net loss of $52.2 million, up from $40 million in Q1 2020. Cash, cash equivalents, and marketable securities totaled $362.7 million as of March 31, 2021.
Alector, a clinical-stage biotechnology company focused on immuno-neurology, announced that its president, Shehnaaz Suliman, will participate in a fireside chat at Stifel’s 3rd Annual CNS Day on April 1, 2021, at 9:30 a.m. ET. The event will be accessible via a live webcast on the Alector website, with a replay available for 30 days afterward. Alector is pioneering treatments for neurodegenerative diseases by targeting immune dysfunction, particularly in Alzheimer's and frontotemporal dementia patient populations.